176 related articles for article (PubMed ID: 22070627)
1. Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.
Ding J; Lemieux C; Chung NN; Schiller PW
Chem Biol Drug Des; 2012 Feb; 79(2):186-93. PubMed ID: 22070627
[TBL] [Abstract][Full Text] [Related]
2. A chimeric opioid peptide with mixed mu agonist/delta antagonist properties.
Weltrowska G; Lemieux C; Chung NN; Schiller PW
J Pept Res; 2004 Feb; 63(2):63-8. PubMed ID: 15009527
[TBL] [Abstract][Full Text] [Related]
3. N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
Weltrowska G; Nguyen TM; Chung NN; Wilkes BC; Schiller PW
Bioorg Med Chem Lett; 2013 Sep; 23(18):5082-5. PubMed ID: 23932788
[TBL] [Abstract][Full Text] [Related]
4. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
[TBL] [Abstract][Full Text] [Related]
5. The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists.
Schiller PW; Weltrowska G; Berezowska I; Nguyen TM; Wilkes BC; Lemieux C; Chung NN
Biopolymers; 1999; 51(6):411-25. PubMed ID: 10797230
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
[TBL] [Abstract][Full Text] [Related]
7. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
[TBL] [Abstract][Full Text] [Related]
8. Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore.
Balboni G; Onnis V; Congiu C; Zotti M; Sasaki Y; Ambo A; Bryant SD; Jinsmaa Y; Lazarus LH; Trapella C; Salvadori S
J Med Chem; 2006 Sep; 49(18):5610-7. PubMed ID: 16942034
[TBL] [Abstract][Full Text] [Related]
9. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
[TBL] [Abstract][Full Text] [Related]
10. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210
[TBL] [Abstract][Full Text] [Related]
11. Bioactivity of new mu and delta opioid peptides.
Capasso A
Med Chem; 2007 Sep; 3(5):480-7. PubMed ID: 17897075
[TBL] [Abstract][Full Text] [Related]
12. Opioid peptide-derived analgesics.
Schiller PW
AAPS J; 2005 Oct; 7(3):E560-5. PubMed ID: 16353933
[TBL] [Abstract][Full Text] [Related]
13. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
[TBL] [Abstract][Full Text] [Related]
14. Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides.
Salvadori S; Attila M; Balboni G; Bianchi C; Bryant SD; Crescenzi O; Guerrini R; Picone D; Tancredi T; Temussi PA
Mol Med; 1995 Sep; 1(6):678-89. PubMed ID: 8529134
[TBL] [Abstract][Full Text] [Related]
15. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
[TBL] [Abstract][Full Text] [Related]
16. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists.
Schiller PW; Nguyen TM; Weltrowska G; Wilkes BC; Marsden BJ; Lemieux C; Chung NN
Proc Natl Acad Sci U S A; 1992 Dec; 89(24):11871-5. PubMed ID: 1334552
[TBL] [Abstract][Full Text] [Related]
17. Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.
Schiller PW; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Lu Y
Life Sci; 2003 Jun; 73(6):691-8. PubMed ID: 12801590
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of dermorphin analogues containing N-substituted amino acids in the 2-position of the peptide sequence.
Schmidt R; Kálmán A; Chung NN; Lemieux C; Horváth C; Schiller PW
Int J Pept Protein Res; 1995 Jul; 46(1):47-55. PubMed ID: 7558596
[TBL] [Abstract][Full Text] [Related]
19. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
[TBL] [Abstract][Full Text] [Related]
20. Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.
Berezowska I; Lemieux C; Chung NN; Wilkes BC; Schiller PW
Chem Biol Drug Des; 2009 Oct; 74(4):329-34. PubMed ID: 19694755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
